[Renal cancer: bone metastases, immunotherapy and interleukin-6]. / Cancer du rein: métastases osseuses, immunothérapie et interleukine 6.

ABSTRACT

In renal cell carcinoma, bone metastases remain a major medical challenge because they are refractory to the antiproliferative effects of immunotherapy. We critically review the biological and clinical data which implicate interleukin-6 in the tumor growth, the pathogenesis of the bone metastases and the response to immunotherapy.